Key facts
- Atech Biotechnology’s last known valuation is $34.8M (Sep 2025).
- It has raised $6.8M; the latest was Later Stage VC ($6.8M) in Sep 2025.
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for Atech Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for Atech Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Atech Biotechnology
Developer of feed yeast derivatives designed for Biotechnology. The company's products mainly include highly active dry yeast, yeast hydrolysate, yeast extract, yeast cell wall, yeast powder, yeast selenium, microecological liquid animal health preparations, and functional protein peptides, providing customers with reliable and innovative products.
- Sector
- Healthcare
- HQ
- Guangzhou, China
- Founded
- 2009
- Employees
- 86
- Website
- en.atechbio.com/
- Ownership
- Privately Held (backing)
Atech Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Atech Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Atech Biotechnology in its N-PORT filings yet. We sweep new filings monthly.